Target Information
General Information of This Target
| Target ID | PATR0EDEOA |
|||||
|---|---|---|---|---|---|---|
| Target Name | Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) |
|||||
| Gene Name | GSPT1; ERF3A |
|||||
| Gene ID | ||||||
| Synonym | ERF3A |
|||||
| Sequence |
MELSEPIVENGETEMSPEESWEHKEEISEAEPGGGSLGDGRPPEESAHEMMEEEEEIPKP
KSVVAPPGAPKKEHVNVVFIGHVDAGKSTIGGQIMYLTGMVDKRTLEKYEREAKEKNRET WYLSWALDTNQEERDKGKTVEVGRAYFETEKKHFTILDAPGHKSFVPNMIGGASQADLAV LVISARKGEFETGFEKGGQTREHAMLAKTAGVKHLIVLINKMDDPTVNWSNERYEECKEK LVPFLKKVGFNPKKDIHFMPCSGLTGANLKEQSDFCPWYIGLPFIPYLDNLPNFNRSVDG PIRLPIVDKYKDMGTVVLGKLESGSICKGQQLVMMPNKHNVEVLGILSDDVETDTVAPGE NLKIRLKGIEEEEILPGFILCDPNNLCHSGRTFDAQIVIIEHKSIICPGYNAVLHIHTCI EEVEITALICLVDKKSGEKSKTRPRFVKQDQVCIARLRTAGTICLETFKDFPQMGRFTLR DEGKTIAIGKVLKLVPEKD Click to Show/Hide
|
|||||
| Family | TRAFAC class translation factor GTPase superfamily, Classic translation factor GTPase family, ERF3 subfamily |
|||||
| Uniprot Entry | ||||||
| HGNC ID | ||||||
| KEGG ID | ||||||
Full List of The ADC Related to This Target
Investigative
| ADC Info | ADC Name | Antibody | Antigen | Payload | Linker | Ref |
|---|---|---|---|---|---|---|
iGAC-3 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
Smol006 |
MP-Ala-Ala-PAB |
[1] | |
iGAC-4 |
undisclosed |
Undisclosed |
Smol006 |
MP-Ala-Ala-PAB |
[1] | |
iGAC-7 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
Smol006 |
MP-Ala-Ala-PAB |
[1] | |
iGAC-8 |
undisclosed |
Undisclosed |
Smol006 |
MP-Ala-Ala-PAB |
[1] | |
iGAC-25 |
pinatuzumab |
Insulin-like growth factor 1 receptor (IGF1R) |
Smol006 |
MP-Ala-Ala-PAB |
[1] | |
iGAC-26 |
gemtuzumab |
Myeloid cell surface antigen CD33 (CD33) |
Smol006 |
MP-Ala-Ala-PAB |
[1] | |
iGAC-31 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
Smol006 |
IG-L-14 linker |
[1] | |
iGAC-34 |
pinatuzumab |
Insulin-like growth factor 1 receptor (IGF1R) |
Smol006 |
IG-L-14 linker |
[1] | |
iGAC-39 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
Smol006 |
MP-Ala-Ala-PAB |
[1] | |
iGAC-57 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
Smol006 |
IG-L-16 linker |
[1] | |
iGAC-58 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
Smol006 |
IG-L-63 linker |
[1] | |
iGAC-59 |
pinatuzumab |
Insulin-like growth factor 1 receptor (IGF1R) |
Smol006 |
IG-L-63 linker |
[1] | |
iGAC-65 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
Smol006 |
IG-L-65 linker |
[1] | |
iGAC-66 |
pinatuzumab |
Insulin-like growth factor 1 receptor (IGF1R) |
Smol006 |
IG-L-65 linker |
[1] | |
iGAC-69 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
Smol006 |
IG-L-68 linker |
[1] | |
iGAC-70 |
pinatuzumab |
Insulin-like growth factor 1 receptor (IGF1R) |
Smol006 |
IG-L-68 linker |
[1] | |
iGAC-97 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
Smol006 |
IG-L-74 linker |
[1] | |
wO2024169913A1 ADC01-01-8 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
Smol006 |
Mc-Val-Cit-PABC |
[2] | |
wO2024169913A1 ADC01-01-4 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
B19 |
Mc-Val-Cit-PABC |
[2] | |
wO2024169913A1 ADC01-02-8 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
B19 |
Mc-Val-Cit-PABC |
[2] | |
wO2024169913A1 ADC01-02-4 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
B19 |
Mc-Val-Ala-PABC |
[2] | |
wO2024169913A1 ADC01-06-8 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
B19 |
Mc-Val-Ala-PABC |
[2] | |
wO2024169913A1 ADC01-06-4 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
B63 |
Mc-Val-Ala-PABC |
[2] | |
wO2024169913A1 ADC01-07-4 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
B63 |
Mc-Val-Ala-PABC |
[2] | |
wO2024169913A1 ADC01-08-8 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
B19 |
(Linker-02)MC-PEG-VA-PAB |
[2] | |
wO2024169913A1 ADC01-08-4 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
B19 |
(Linker-03)SMCC-TAZ-PEG-VC-PAB |
[2] | |
wO2024169913A1 ADC03-01-8 |
SYM003 (anti-Claudin 18.2) |
Claudin-18.2 (CLDN18.2) |
B19 |
(Linker-03)SMCC-TAZ-PEG-VC-PAB |
[2] | |
wO2024169913A1 ADC03-01-4 |
SYM003 (anti-Claudin 18.2) |
Claudin-18.2 (CLDN18.2) |
B19 |
Mc-Val-Cit-PABC |
[2] | |
wO2024169913A1 ADC04-01-8 |
SYM004 (anti-DLL3) |
Delta-like protein 3 (DLL3) |
B19 |
Mc-Val-Cit-PABC |
[2] | |
wO2024169913A1 ADC04-02-8 |
SYM004 (anti-DLL3) |
Delta-like protein 3 (DLL3) |
B19 |
Mc-Val-Cit-PABC |
[2] | |
wO2024169913A1 ADC04-06-8 |
SYM004 (anti-DLL3) |
Delta-like protein 3 (DLL3) |
B19 |
Mc-Val-Ala-PABC |
[2] | |
wO2024169913A1 ADC04-06-4 |
SYM004 (anti-DLL3) |
Delta-like protein 3 (DLL3) |
B63 |
Mc-Val-Ala-PABC |
[2] | |
wO2024169913A1 ADC04-07-8 |
SYM004 (anti-DLL3) |
Delta-like protein 3 (DLL3) |
B63 |
Mc-Val-Ala-PABC |
[2] | |
wO2024169913A1 ADC04-07-4 |
SYM004 (anti-DLL3) |
Delta-like protein 3 (DLL3) |
B19 |
(Linker-02)MC-PEG-VA-PAB |
[2] | |
wO2024169913A1 ADC04-08-8 |
SYM004 (anti-DLL3) |
Delta-like protein 3 (DLL3) |
B19 |
(Linker-02)MC-PEG-VA-PAB |
[2] | |
wO2024169913A1 ADC04-08-4 |
SYM004 (anti-DLL3) |
Delta-like protein 3 (DLL3) |
B19 |
(Linker-03)SMCC-TAZ-PEG-VC-PAB |
[2] | |
wO2024169913A1 ADC04-09-8 |
SYM004 (anti-DLL3) |
Delta-like protein 3 (DLL3) |
Smol006 |
Mc-Val-Cit-PABC |
[2] | |
wO2024169913A1 ADC04-09-4 |
SYM004 (anti-DLL3) |
Delta-like protein 3 (DLL3) |
Smol006 |
Mc-Val-Cit-PABC |
[2] | |
wO2024169913A1 ADC07-01-8 |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
B19 |
Mc-Val-Cit-PABC |
[2] | |
wO2024169913A1 ADC07-01-4 |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
B19 |
Mc-Val-Cit-PABC |
[2] | |
wO2024169913A1 ADC07-02-8 |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
B19 |
Mc-Val-Ala-PABC |
[2] | |
wO2024169913A1 ADC07-02-4 |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
B19 |
Mc-Val-Ala-PABC |
[2] | |
wO2024169913A1 ADC07-06-8 |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
B63 |
Mc-Val-Ala-PABC |
[2] | |
wO2024169913A1 ADC07-06-4 |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
B63 |
Mc-Val-Ala-PABC |
[2] | |
wO2024169913A1 ADC07-08-8 |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
B19 |
(Linker-03)SMCC-TAZ-PEG-VC-PAB |
[2] | |
wO2024169913A1 ADC07-08-4 |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
B19 |
(Linker-03)SMCC-TAZ-PEG-VC-PAB |
[2] | |
wO2024169913A1 ADC07-09-8 |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
Smol006 |
Mc-Val-Cit-PABC |
[2] | |
wO2024169913A1 ADC07-09-4 |
Pertuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
Smol006 |
Mc-Val-Cit-PABC |
[2] | |
wO2024169913A1 ADC08-01-8 |
Belantamab |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
B19 |
Mc-Val-Cit-PABC |
[2] | |
wO2024169913A1 ADC08-01-4 |
Belantamab |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
B19 |
Mc-Val-Cit-PABC |
[2] | |
wO2024222841A1 ADC38 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
(S)B19 |
OXDc-VA-PAB (PEG) |
[3] | |
wO2024222841A1 ADC38-4 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
(S)B19 |
OXDc-VA-PAB (PEG) |
[3] | |
wO2024222841A1 ADC39 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
(S)B19 |
OXD-VA-PAB (PEG) |
[3] | |
wO2024222841A1 ADC40 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
(S)B19 |
OXDc-VA-PAB (Glu) |
[3] | |
wO2024222841A1 ADC41 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
(S)B19 |
OXD-VA-PAB (Glu) |
[3] | |
wO2024222841A1 ADC42 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
B19 |
OXDc-VA-PAB (PEG) |
[3] | |
wO2024222841A1 ADC43 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
(R)B19 |
OXDc-VA-PAB (PEG) |
[3] | |
wO2024222841A1 ADC44 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
B61 |
OXDc-VA-PAB (PEG) |
[3] | |
wO2024222841A1 ADC45 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
B63 |
OXDc-VA-PAB (PEG) |
[3] | |
wO2024222841A1 ADC55 |
018 (CD33) |
Myeloid cell surface antigen CD33 (CD33) |
(S)B19 |
OXDc-VA-PAB (PEG) |
[3] | |
wO2024222841A1 ADC56 |
019 (CD33) |
Myeloid cell surface antigen CD33 (CD33) |
(S)B19 |
OXDc-VA-PAB (PEG) |
[3] | |
wO2024222841A1 ADC57 |
020 (CD33) |
Myeloid cell surface antigen CD33 (CD33) |
(S)B19 |
OXDc-VA-PAB (PEG) |
[3] | |
wO2024222841A1 ADC58 |
021 (CD33) |
Myeloid cell surface antigen CD33 (CD33) |
(S)B19 |
OXDc-VA-PAB (PEG) |
[3] | |
wO2024222841A1 ADC59 |
022 (CD33) |
Myeloid cell surface antigen CD33 (CD33) |
(S)B19 |
OXDc-VA-PAB (PEG) |
[3] | |
wO2024222841A1 ADC60 |
023 (CD123) |
Interleukin-3 receptor subunit alpha (IL3RA) |
(S)B19 |
OXDc-VA-PAB (PEG) |
[3] | |
wO2024222841A1 ADC62-4 |
008 (BCMA) |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
(S)B19 |
OXDc-VA-PAB (PEG) |
[3] | |
wO2024222841A1 ADC62 |
008 (BCMA) |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
(S)B19 |
OXDc-VA-PAB (PEG) |
[3] | |
wO2024222841A1 ADC64-4 |
008 (BCMA) |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
(S)B19 |
Undisclosed |
[3] | |
wO2024222841A1 ADC64 |
008 (BCMA) |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
(S)B19 |
Undisclosed |
[3] | |
wO2024222841A1 ADC65 |
019 (CD33) |
Myeloid cell surface antigen CD33 (CD33) |
B63 |
Mc-Val-Ala-PABC |
[3] | |
wO2024222841A1 ADC66 |
022 (CD33) |
Myeloid cell surface antigen CD33 (CD33) |
B63 |
Mc-Val-Ala-PABC |
[3] | |
wO2024222841A1 ADC67 |
023 (CD123) |
Interleukin-3 receptor subunit alpha (IL3RA) |
(S)B19 |
Mc-Val-Ala-PABC |
[3] | |
t-ADC-2 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
(S)B19 |
OXDc-VA-PAB (PEG) |
[3] | |
t-ADC |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
(S)B19 |
OXDc-VA-PAB (PEG) |
[3] | |
wO2024222841A1 ADC39-4 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
(S)B19 |
OXD-VA-PAB (PEG) |
[3] | |
wO2024222841A1 ADC40-4 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
(S)B19 |
OXDc-VA-PAB (Glu) |
[3] | |
wO2024222841A1 ADC41-4 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
(S)B19 |
OXD-VA-PAB (Glu) |
[3] | |
wO2024222841A1 ADC42-4 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
B19 |
OXDc-VA-PAB (PEG) |
[3] | |
wO2024222841A1 ADC43-4 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
(R)B19 |
OXDc-VA-PAB (PEG) |
[3] | |
wO2024222841A1 ADC44-4 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
B61 |
OXDc-VA-PAB (PEG) |
[3] |
References